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Michael D. Sintchak, Mark A. Fleming, Olga Futer, is also found in bacteria and protozoa, and these forms
share 30%±40% sequence identity with the human en-Scott A. Raybuck, Stephen P. Chambers,
Paul R. Caron, Mark A. Murcko, zyme (Natsumeda and Carr, 1993). Regardless of spe-
cies, native IMPDHs exist as homotetramers with sub-and Keith P. Wilson
Vertex Pharmaceuticals Incorporated unit molecular masses in the 56±58 kDa range (Carr et
al., 1993) and followan ordered Bi±Bi reaction sequence,40 Allston Street
Cambridge, Massachusetts 02139-4211 where IMP binding precedes that of NAD, and reduced
nicotinamide adenine dinucleotide (NADH) is released
prior to XMP (Holmes et al., 1974; Carr et al., 1993). This
mechanism is different from that of most other knownSummary
NAD-dependent dehydrogenases, which have either a
random order of substrate addition or require that NADThe structure of inosine-59-monophosphate dehydro-
bind before substrate.genase (IMPDH) in complex with IMP and mycophe-
Mycophenolic acid (MPA; Figure 1) was discoverednolic acid (MPA) has been determined by X-ray diffrac-
in 1896 as a fermentation product of several Penicilliumtion. IMPDH plays a central role in B and T lymphocyte
species (Gosio, 1896) and is a potent uncompetitivereplication. MPA is a potent IMPDH inhibitor and the
reversible inhibitor of IMPDH (Franklin and Cooke, 1969).active metabolite of an immunosuppressive drug re-
MPA binds to IMPDH after NADH is released but beforecently approved for the treatment of allograft rejec-
XMP is produced (Hedstrom and Wang, 1990; Link andtion. IMPDH comprises two domains: a core domain,
Straub, 1996). Reported Ki values for human type IIwhich is an a/b barrel and contains the active site,
IMPDH are 6±10 nM (Carr et al., 1993; Hager et al., 1995),and a flanking domain. The complex, in combination
and estimates for the human type I enzyme vary fromwith mutagenesis and kinetic data, provides a struc-
11 nM (Hager et al., 1995) to 33±37 nM (Carr et al.,tural basis for understanding the mechanism of IMPDH
1993). It is not clear which isoform is the more importantactivity and indicates that MPA inhibits IMPDH by act-
therapeutic target. Early reports indicated that onlying as a replacement for the nicotinamide portion of
IMPDH type II was up-regulated during proliferation ofthe nicotinamide adenine dinucleotide cofactor and a
lymphatic and leukemic cell lines (Konno et al., 1991;catalytic water molecule.
Nagai et al., 1991, 1992; Collart et al., 1992), but recent
studies in T cells revealed similar increases in the mRNAIntroduction
levels of both isoforms following mitogenic stimulation
(Dayton et al., 1994). Mycophenolate mofetil, the mor-Proliferating B and T lymphocytes are singularly depen-
pholinoethyl ester prodrug of MPA, was recently ap-dent on the de novo pathway, rather than the salvage
proved for the prevention of acute allograft rejectionpathway, for purine biosynthesis (Allison et al., 1977).
following kidney transplant (Shaw et al., 1995; Sollinger,Modulation of this metabolic pathway, with broad thera-
1995), which demonstrates the importance of IMPDH inpeutic potential, involves the pharmaceutical inhibition
the cellular immune response.of inosine-59-monophosphate dehydrogenase (IMPDH;
We report the X-ray crystal structure of Chinese ham-EC 1.1.1.205).
ster (Cricetulus griseus) IMPDH in complex with IMPIMPDH catalyzes the nicotinamide adenine dinuc-
and MPA at 2.6 AÊ resolution (Table 1). We have con-leotide (NAD)-dependent oxidation of inosine-59-mono-
firmed that human type II and Chinese hamster IMPDH,phosphate (IMP) to xanthosine-59-monophosphate
which differ by only six amino acids (Collart and Huber-(XMP), which is the committed step in de novo guano-
mann, 1988), have similar enzymatic characteristicssine nucleotide biosynthesis (Crabtree and Henderson,
(data not shown) and areboth strongly inhibited by MPA.1971; Snyder et al., 1972; Jackson et al., 1975; Weber,
The structure, in combination with kinetic and mutagen-1983). This reaction is particularly important to B and T
esis data, better defines the enzymatic mechanism oflymphocytes, which depend on IMPDH activity togener-
IMPDH and reveals the exact nature of the inhibition ofate the guanosine nucleotide levels needed to initiate a
IMPDH by MPA.proliferative response to mitogen or antigen (Allison et
al., 1975). Increased IMPDH activity has also been ob-
served in rapidly proliferating human leukemic cell lines, Results
solid tumor tissues, and other replicating cell types (Nat-
sumeda et al., 1988; Collart and Hubermann, 1990; Global Fold and Tetramer Contacts of IMPDH
Each IMPDH monomer consists of two domains (FigureKonno et al., 1991; Nagai et al., 1991, 1992; Collart et
al., 1992; Nakamura et al., 1992; Senda and Natsumeda, 2). The larger domain had approximate dimensions of
40 3 40 3 50 AÊ and formed an a/b barrel. This finding is1994). Thus, IMPDH is a target for cancer as well as im-
munosuppressive chemotherapy (Jackson et al., 1975). consistent with structure predictions based on primary
sequence (Bork et al., 1995). The active-site loop (resi-Isoforms (2) of human IMPDH, designated type I and
type II, have been identified (Collart and Hubermann, dues 325±342) starts just after strand6, and like all barrel
enzymes examined to date, resides at the C-terminal1988; Natsumeda et al., 1990). Each contains 514 amino
acids, and they share 84% sequence identity. IMPDH end of the barrel b strands. Comparisons of this domain
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Figure 1. MPA and MPA Analogs
Chemical structure of MPA and three ana-
logs, along with IC50 values as reported in
Syntex patents (Sjogen, 1995; Artis et al.,
1995). The IC50 data are based on an in vitro
assay that measures the formation of NADH
by UV/VIS spectroscopy at 340 nm.
of IMPDH with proteins in the Protein Data Bank identi- the second a helix and third b strand of the barrel. The
subdomain has rough dimensions of 20 3 20 3 40 AÊfied glycolate oxidase, tryptophan synthase, and indole-
3-glycerol phosphate synthase as enzymes with similar and protrudes from the N-terminal side of the barrel
core (Figure 2). IMPDH is unique among a/b barrels infolds and C-terminal phosphate-binding sites. The clos-
est known structural homolog to IMPDH is glycolate this regard. A comparison of IMPDH to aligned protein
structures in the FSSP database (Holm and Sander,oxidase, with a backbone root-mean-square deviation
of 1.49 AÊ over 172 residues. The sequence of glycolate 1996) located only 15 amino acids as the next largest
insertion at the N-terminal end of any a/b barrel. In addi-oxidase also shows local homology to that of IMPDH,
with 40% identity over 40 amino acids in the region tion, sequence comparisons identified GMP reductase
as the closest IMPDH homolog, but the subdomain resi-surrounding the phosphate-binding site.
The smaller flanking domain (designated subdomain dues are absent in this enzyme (Andrews and Guest,
1988). The sequence and fold of the subdomain alsohere) includes residues 110±244 and is inserted between
Table 1. Statistics for Data Collection and Structure Determination
Native tet-HgCl bis-Hg bis-Hg
Data Collection (imp 1 mpa) K2WO4 (NH)2 WS4 PCMBS 1 PCMBS 2 PbCl EuCl3 furan bi-thiophene benzofuran
Resolution (A8 ) 2.6 3.5 4.5 4.0 4.0 4.0 3.0 3.2 2.0 2.9
Observations 123,246 45,765 10,610 27,429 40,754 19,998 139,573 113,378 113,758 114,000
Unique Reflections 37,492 16,341 5,363 10,222 10,719 9,792 25,060 19,805 27,766 27,230
Completeness (%) 93 93 64 86 89 82 99 87 92 93
Rsym 5.2 7.4 13.4 6.7 8.7 8.3 10.7 9.1 6.6 6.6
MIR Phasing
Resolution (A8 ) 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0
Riso 5.9 11.7 13.6 26.0 8.1 14.2 18.5 11.4 14.3
number of sites 3 4 6 11 1 3 5 3 6
Rcullis 0.73 0.76 0.68 0.54 0.77 0.69 0.60 0.57 0.58
Phasing power 0.90 0.52 0.80 1.41 0.49 0.76 2.03 2.71 2.75
Mean overall FOM 0.79
Refinement
Resolution 8.0±2.6
Rcryst (%) 21.7
Rfree (%) 28.5
Nonhydrogen atoms 6,101
Water molecules 202
root-mean-square deviation
Bond lengths (A8 ) 0.007
Bond angles (8) 1.627
Dihedrals (8) 22.27
Impropers (8) 1.269
For definitions, see Blundell and Johnson (1976).
(Figure 2 legend continued)
not visible in electron density maps are marked ª???.º The flap (residues 400±450) between strand b8 and helix a8 includes strands bJ±bN
and helix aE. Residue assignments for the strands and helices that form the a/b barrel are as follows: b1, residues 65±68; a1, 76±85; b2,
88±91; a2, 98±109; b3, 245±250; a3, 256±266; b4, 270±274; a4, 281±293; b5, 298±302; a5, 307±316; b6, 320±324; a6, 343±355; b7, 360±364;
a7, 370±378; b8, 382±386; and a8, 456±469. Residue assignments for the remaining secondary structural elements are as follows: bA, residues
18±19; bB, 35±38; bC, 40±42; bD, 53±55; bE, 59±61; bF, 114±116; bG, 186±189; bH, 206±212; bI, 220±223; bJ, 400±402; bK, 406±409; bL,
411±413; bM, 438±440; bN, 443±448; bO, 489±492; bP, 509±513; aA, 21±23; aB, 194±200; aC, 225±232; aD, 333±337; aE, 416±420; aF, 476±484;
and aG, 495±501.
IMPDH in Complex with Immunosuppressant MPA
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Figure 2. Structure and Topology of IMPDH
(A) Stereo ribbon diagram (Carson, 1991) of IMPDH. The structure is viewed from the C-terminal end of the b strands (yellow) that form the
a/b barrel. The a helices (red) on the outside of the barrel are labeled a1±a8. The portion of the subdomain (orange) that is ordered is shown.
Cys-331 (green) is labeled and sits over one end of the barrel. An arrow marks the location of the flap (residues 400±450) that, together with
the active-site loop, helps form the active-site pocket.
(B) Topology diagram of the IMPDH fold. Secondary structure was assigned using the Kabsch and Sander algorithm (Kabsch and Sander,
1983), along with visual inspection. The b strands and a helices that form the a/b barrel core are labeled b1±b8 and a1±a8. The strands and
helices that are not part of the barrel are labeled bA±bP and aA±aG. Cys-331 is located on the loop between strand b6 and helix aD. The
subdomain starts after helix a2 and ends at strand b3 and includes strands bF±bI and helices aB and aC. Parts of the structure that were
(Figure 2 legend continued on previous page)
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appeared to be novel, as no corresponding matches MPA is a potent (Ki 5 11 nM) uncompetitive inhibitor
of Chinese hamster IMPDH, and the structure revealscould be found. The function of the subdomain in IMPDH
is not known, and the structure reveals that this domain many interactions between MPA and IMPDH active-site
residues (Figure 4). One face of the bicyclic ring systemis 35 AÊ away from the active site and is relatively disor-
dered (Figure 2). There is considerable variation in the is stacked on the XMP* hypoxanthine ring, while the
other makes contact with the main-chain atoms of Ser-size and sequence of this region among IMPDHs from
different species, including Borrelia burgdorferi IMPDH 276. Together, the hexenoic acid tail, methyl substituent,
and methoxy group of MPA make van der Waals con-(Genbank accession number U13372), which lacks most
of the subdomain residues. A deletion mutant that re- tacts with the side-chain atoms of Asp-274, Ser-275,
Ser-276, Asn-303, Arg-322, and Gln-441. Hydrogenplaces the entire subdomain in human type II IMPDH
with a short peptide linker has been made, and the bonds (6) between the drug and IMPDH were also ob-
served. These included hydrogen bonds between thetruncated enzyme is fully active in vitro (our unpublished
data). O2 lactone oxygen and the amide nitrogen of Gly-326,
and the C1 carbonyl oxygen and hydroxyl group of Thr-IMPDH is active in solution and crystallizes as a tetra-
mer,and extensive contacts between barrels of adjacent 333. The hexenoic acid tail of MPA adopts a bent confor-
mation, unlike the extended conformation seen in themonomers helped stabilize this form (Figure 3). Most of
the tetramer-related contacts arose from residues near nuclear magnetic resonance studies (Makara et al.,
1996) and crystal structure of free MPA (Harrison et al.,the N- and C-terminus of one subunit that contacted
amino acids that were part of or near the active site 1972). This conformation allows the carboxylate group
to form hydrogen bonds with the amide nitrogen andof an adjacent subunit. These interactions may help
stabilize the active-site conformation. The subdomain side-chain hydroxyl groups of Ser-276. Additionally, the
C7 phenolic oxygen forms hydrogen bonds to the side-made no tetramer contacts.
chain hydroxyl group of Thr-333 and the side-chain am-
ide of Gln-441.
The Active Site
We have determined the structure of IMPDH in complex
with MPA and an IMP reaction intermediate that is gen- Mutational and Kinetic Analysis of the Active Site
erated during substrate turnover. In this inhibited state, We generated a series of mutants to explore the roles
hydride transfer and NADH release has occurred, but of human type II IMPDH active-site residues in catalysis
XMP has not been produced (Link and Straub, 1996; and inhibitor binding (Figure 5). Knowledge of the three-
Fleminget al., 1996). Thus,MPA and an IMP intermediate dimensional structure permitted rationalization of the
are bound in the active site simultaneously. This obser- observed phenotype. Mutation of either Cys-331 or Asp-
vation is consistent with the uncompetitive inhibition of 364 to Ala effectively abolished IMPDH activity relative
IMPDH by MPA. The electron density in the active site to wild type. The crystal structure revealed that Cys-
clearly shows that a covalent bond is formed between 331 formed a covalent bond to XMP*, confirming its role
the C2 carbon of IMP and the sulfur atom of Cys-331 in catalysis, while the side chain of Asp-364 formed a
(Figure 4) to yield an oxidized IMP thioimidate intermedi- hydrogen bond to the ribose moiety of XMP*. Changing
ate (XMP*). Cys-331 has also been shown to form a Ser-329 to Ala reduced enzyme activity to 13% of the
covalent bond with 14C8-IMP when NAD is present wild-type level. This side chain formed a hydrogen bond
(Huete-Perez et al., 1995; Link and Straub, 1996). In to the phosphate of XMP*. Residues that made direct
addition, Cys-331 forms a covalent bond to 6-Cl IMP contact with MPA were also modified. Substituting Thr-
and EICARMP, compounds which irreversibly inactivate 333 with Ile and Gln-441 with Ala increased the Ki ap-
IMPDH (Antonino et al., 1994; Wang et al., 1996). To- parent of MPA 300-fold and 25-fold, respectively. The
gether, these observations establish an important role Thr-333→Ile mutation is of particular interest, since it
for this residue in catalysis. has been observed in murine blastoma cells selected
In addition to the covalent bond to Cys-331, many for 10,000-fold increased resistance to MPA (Hodges,
other interactions between XMP* and the enzyme were 1989; Lightfoot and Snyder, 1994). The crystal structure
observed (Figure 4). The phosphate moiety forms hydro- showed a hydrogen bond network between Thr-333,
gen bonds with four backbone amide nitrogen atoms Gln-441, and MPA, with the phenolic oxygen in particu-
and the side-chain hydroxyl groups of Tyr-411 and Ser- larly good hydrogen bonding distance and geometry
329. Tyr-411 is located on one of a pair of b strands with the side-chain hydroxyl of Thr-333 (see Figure 4).
(residues 406±413 and 443±448) that are part of a flap The carboxylate group of the hexenoic acid tail of MPA
(residues 400±450) that makes three hydrogen bonds formed two hydrogen bonds with Ser-276. Mutating this
with the hypoxanthine ring. Together, these interactions residue to Ala disrupted this interaction and led to a
may help order this region of IMPDH. This hypothesis 7-fold increase in Ki apparent. In contrast, mutations of
is supported by proteolysis experiments that show that other active-site residues, such as Ser-275, Ser-327,
IMPDH is protected from cleavage by elastase after and Gln-368, had little effect on catalytic activity or drug
residues 437 and 440 when IMP is present (Nimmesgern inhibition. The structure indicates that these residues
et al., submitted). The ribose ring, which adopts a C39- do not contact substrate or inhibitor directly.
endo conformation, also contributes significantly to
binding. The structure shows that the O29 and O39 hy-
droxyl groups form a hydrogen-bonding network to Ser- IMPDH Dependence on Potassium
Kinetic experiments with human IMPDH reveal that, al-68 and Asp-364. Van der Waals contacts between XMP*,
Met-70, and Ile-330 were also observed. though IMP can bind to the enzyme in the absence of
IMPDH in Complex with Immunosuppressant MPA
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Figure 3. Structure of the IMPDH Tetramer
Ribbon drawing (Carson, 1991) of the IMPDH tetramer, viewed down the crystallographic 4-fold axis. Each IMPDH monomer is colored
differently. The white outline represents the solvent-accessible surface. Most of the tetramer-related contacts are made between adjacent
barrels, and the surface area buried at each subunit interface is approximately 4000 AÊ 2. Bound potassium ions (white spheres) are seen
adjacent to Cys-331 at each subunit interface. Several other contacts are noteworthy. Residues 41±43 form a b strand parallel with residues
279±281 in an adjacent subunit. Residues 502±503 make van der Waals contact with Cys-331 in an adjacent subunit. Residues 507±510 form
an antiparallel b strand with residues 444±447 of the active-site flap of an adjacent subunit, and these two strands can be seen above the
potassium ions.
potassium, this ion is required for the reaction to pro- residues near the C-terminus of an adjacent IMPDH sub-
unit, suggesting that potassium may also stabilize theceed (Xiang et al., 1996). The structure explains this
observation. We observed a large peak in difference tetramer form of IMPDH (see Figure 3).
electron-density maps that was surrounded by a water
molecule and five main-chain carbonyl oxygens, includ- Discussion
ing that of Cys-331 (data not shown). The average dis-
tance of the peak center to each of the surrounding Proliferating B and T lymphocytes are singularly depen-
dent on the de novo, as opposed to salvage, pathwayligands was 3.1 AÊ , and the peak was hexagonally coordi-
nated. The nature and positioning of the ligands sug- for purine biosynthesis. Inhibitors of IMPDH, which cata-
lyzes the rate-limiting step in the de novo synthesisgested a potassium-binding site. Thus, potassium may
organize protein conformation around the active site of guanosine nucleotides, have been shown to have a
strong immunosuppressive effect. One such compoundand could help position Cys-331 for catalysis. In addi-
tion, three of the carbonyl oxygen ligands resided on is MPA. The ternary complex described here reveals
Cell
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Figure 4. IMPDH Active-Site Electron Density and Interactions
(A) Stereo view of the IMPDH active-site electron density (Carson, 1991). Refined coordinates of the IMP thioimidate intermediate and MPA
are shown in thick bonds superimposed on the SigmaA-weighted (Read, 1986) 2Fobs±Fcalc electron density contoured at 2.0 s. Carbon atoms
are green, nitrogen atoms blue, oxygen red, sulfur yellow, and phosphorous purple. The hypoxanthine ring makes a covalent bond to the
sulfur of Cys-331. Side chains that interact with substrate or inhibitor to form the active-site pocket are shown using thin bonds. These
interactions should also apply to the human type II form of IMPDH. There are only six differences in amino acid sequence between Chinese
hamster and human type II IMPDH (R173C, N215D, L265Q, M290I, E292D, and C327S). These side chains are all at least 15 AÊ away from the
active site, except C327S, which is a conservative mutation and points away from the active-site pocket.
(B) Schematic representation of the XMP*±IMPDH interactions. There is a covalent bond between the sulfur atom of Cys-331 and the C2
carbon of the hypoxanthine ring.
(C) Schematic representation of the MPA±IMPDH interactions. All proximal water molecules observed in electron density difference maps are
labeled ªH2O.º All distances pertain to nonhydrogen atoms.
IMPDH in Complex with Immunosuppressant MPA
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Figure 5. Mutational and Kinetic Analysis of
the Active Site
(A) Specific activity of IMPDH mutants for IMP
substrate. Second-order rate constants (k
cat/Km, M21sec21) were calculated from IMP
titration data at 400 mM NAD concentration,
obtained by monitoring the rate of NADH pro-
duction at 340 nmat 378C. We have confirmed
that 400 mM NAD is saturating for all mutants
depicted here.
(B) Inhibition of mutant IMPDH proteins by
MPA. Ki apparent values for MPA were ob-
tained from the rate versus inhibitor data of
IMPDH mutants at saturating IMP and NAD
concentrations. The data were fit to the equa-
tion for tight-binding uncompetitive inhibition
using the program KineTic 3.0 (Morrison,
1969).
much about the structure and mechanism of IMPDH and nicotinamide ring and the bound substrate, and as ob-
served in the structures of glutathione reductase andprovides atomic level details of an immunosuppressant
inhibiting its cellular target. NADH peroxidase. It is also known that hydride transfer
occurs on the b face of NAD (Cooney et al., 1987). If no
large conformational changes occur between the time
Enzymatic Mechanism of IMPDH NADH leaves and MPA binds, these structural consider-
and Inhibition by MPA ations support an earlier prediction (Hedstrom and
The IMPDH catalyzed oxidation of IMP results in transfer Wang, 1990) that during hydride transfer the nicotin-
of hydrogen to the nicotinamide ring of NAD, forming amide of NAD occupies a position similar to the 6,5 ring
NADH and XMP. Since direct transfer of the hydride system of MPA. In this orientation, the nicotinamide
is energetically unfavorable, two mechanisms involving amide moiety would form hydrogen bonds with Gly-324,
activation of IMP at the inosine C2 position have been Thr 333, Gly-326, and Asn-303.
proposed (Hedstrom and Wang, 1990). In the first mech- The structure of the inhibited complex also indicates
anism, water, aided by an active-site base to provide that the phenolic hydroxyl group of MPA, which forms
OH2 attack, is added in an initial step at C2. Hydride hydrogen bonds to Thr-333 and Gln-441, may be a re-
transfer to NAD then occurs from the tetrahedral inter- placement for the catalytic water that hydrolyzes the
mediate thus formed, producing the enol tautomer of thioimidate intermediate to produce XMP. In the ab-
XMP. In the second mechanism, nucleophilic attack on sence of MPA, a water molecule in the vicinity of the
IMP occurs from an active-site cysteine thiol. This is MPA hydroxyl would be stabilized by hydrogen bonds
followed by hydride transfer to NAD to yield a covalently with Thr-333 and Gln-441 and would be properly posi-
bound thioimidate intermediate that is hydrolyzed to tioned for nucleophilic attack at the C2 carbon of the
XMP in a subsequent step.The crystal structure, in com- thioimidate intermediate. Therefore, structural features
bination with recent results that also demonstrate the of the bound orientation of MPA indicate that it is both
formation of an IMPDH±substrate covalent adduct a nicotinamide ring and a catalytic water mimic. This
(Huete-Perez et al., 1995; Link and Straub, 1996), hypothesis is consistent with a report that des-hydroxy-
strongly supports the second mechanism. The direct MPA is at least 1000-fold less potent in a cellular assay
observation of the covalently bound thioimidate as the than MPA (Or et al., 1995, Am. Chem. Soc., poster). It
oxidized IMP intermediate confirms that enzyme-cata- has also been shown that the presence of a hydroxyl
lyzed oxidation of IMP occurs via attack of Cys-331 at group which is able to mimic a catalytic water molecule
the C2 positionand excludes a general base mechanism can lead to as much as a 10 kcal/mol improvement in
where water is added to the inosine ring in an early step. binding (Wolfendon and Kati, 1991). Additional active-
Other aspects of the IMPDH catalyzed reaction can site mutants, coupled with substrate and MPA analog
be addressed with the crystal structure. Although the studies underway, will test these hypotheses.
MPA inhibited complex does not contain NAD or NADH,
a combination of structural and chemical evidence Inhibition of IMPDH by Analogs of MPA
allows the nicotinamide ring to be modeled into the The crystal structure of the MPA±inhibited complex
active site. The nicotinamide ring must be oriented to helps to explain some of the known structure±activity
allow hydride transfer from the C2 position of IMP to data for analogs of MPA (Figure 1), which also bind as
the C4 position of NAD. Further, hydride transfer occurs uncompetitive inhibitors (data not shown). Replacement
more readily if the nicotinamide and hypoxanthine rings of the phenolic hydroxyl by amino leads to an 8-fold
are nearly parallel (Wu et al., 1995), consistent with the reduction in potency (Sjogen, 1995). The structure indi-
cates that this change would result in the loss of onefavorable interactions provided by stacking between the
Cell
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hydrogen bond in the network between MPA, Thr-333, site contains an IMP intermediate covalently linked to
Cys-331, which confirms the correct enzymatic mecha-and Gln-441 (Figure 4). More dramatic changes to the
hydroxyl group that increase the steric bulk can reduce nism for IMPDH. The structure also indicates that MPA
inhibits the enzyme by simultaneously mimicking thepotency by 1000-fold or more (Sjogen, 1995). The por-
tion of the active site that surrounds the phenolic hy- nicotinamide portion of the NAD cofactor and a catalytic
water molecule. We observe K1 ion bound near thedroxyl group is tightly packed and cannot accommodate
additional atoms. Significant variations in potency are active site and tetramer interface, which explains the
dependence on this cation for enzyme activity. Further,also seen in MPA analogs that alter the hexenoic acid
side chain. Reduction of the carboxylate group to the we find that IMPDH contains a unique phosphate-bind-
ing site, which reveals in part the specificity of MPA foralcohol, or esterification, leads to a 50-fold reduction
in IMPDH inhibition (D. Armistead, unpublished data). IMPDH versus other NAD-binding enzymes.
The structural information should facilitate the devel-These changes would interfere with hydrogen bonding
to Ser-276. Examples of constrained side-chain com- opment of more efficacious IMPDH inhibitors that ad-
dress the limitations of MPA. Mycophenolate mofetilpounds that are more potent in vitro IMPDH inhibitors
than MPA have been disclosed (Artis et al., 1995). Ab (CellCeptTM), a prodrug of MPA which quickly liberates
free MPA in vivo, is an effective immunosuppressantinitio and molecular dynamics calculations indicate that
many of these analogs have low-energy conformations available for the prevention of rejection following kidney
transplantation (Shaw et al., 1995; Sollinger, 1995). Sev-that preserve the hydrogen bonds with Ser-276 while
reducing the entropy of the hexenoic acid side chain. eral clinical observations, however, limit the therapeutic
potential of this drug (Shaw et al., 1995). MPA is rapidly
metabolized to the glucuronide in vivo, which then un-Similarity of IMPDH to Other Enzymes
dergoes enterohepatic recycling (Allison and Eugui,Insight into the structure and mechanism of related en-
1993). This metabolic profile leads to accumulation ofzymes is revealed in part by the IMPDH structure. Se-
drug substance in the gastrointestinal tract (Shaw et al.,quence database searching identified GMP reductase
1995; P. Chaturvedi, unpublished data), thereby low-as the closest IMPDH homolog, with 63% similarity and
ering the in vivo potency and contributing togastrointes-37% identity over a region of 150 amino acids that in-
tinal side effects. Novel IMPDH inhibitors designed included the active-site cysteine as well as the phosphate
part from the structural information presented here maybinding site. The high level of sequence conservation
result in improved therapeutics for use in cancer andaround the active site suggests that GMP reductase has
immunosuppressive chemotherapy.a similar fold and active-site geometry to IMPDH. This
is supported by the observation that GMP reductase,
Experimental Procedures
like IMPDH, binds substrate before cofactor (Spector et
al., 1979). Crystallization and Data Collection
The structure of the IMPDH a/b barrel is similar to Details of sample preparation for crystallization are described else-
where (Fleming et al., 1996). Crystals of inhibited Chinese hamsterthat of other flavin and nicotinamide-dependent oxido-
IMPDH were grown by vapor diffusion when protein (20 mg ml21 inreductases, including glycolate oxidase, the NADPH-
300 mM KCl, 10% glycerol, 2 mM MPA, 2 mM 2-mercaptoethanol,dependent aldo-keto reductases, and triethylamine
2 mM EDTA, 50 mM Tris [pH 8.0]) was mixed with reservoir (10%
dehydrogenase. The C-terminally sequence-encoded polyethylene glycol 6K, 1 M LiCl, 100 mM morpholinoethyl sulfonic
phosphate-binding site is also conserved, but in IMPDH acid, 5% 1-methyl-2-pyrrolidinone [v/v], 40 mM 2-mercaptoethanol
this site is occupied by the IMP ribose phosphate, rather [pH 5.8]) at a 4:2 ratio and allowed to standover the reservoir solution
at 228C. Crystals were equilibrated using reservoir solution plus 9%than by the phosphates of the flavin or nicotinamide
glycerol and 2 mM MPA prior to heavy atom derivitization and thenadenine dinucleotide phosphate (NADP) cofactors as
cryoprotected with reservoir solution plus 15% glycerol just beforeseen in the other enzymes. This suggests that the NAD
X-ray data collection at 21658C. All data were collected on R-AXIS
binding site in IMPDH is novel and may help explain the IIC imaging plates andprocessed using the software of the manufac-
specificity seen with inhibitors that bind in this site, such turer (Molecular Structure Corp.). The crystals belong to space
as MPA and thiazole adenine dinucleotide (Lee et al., group P4, with unit cell dimensions a 5 b 5 110.6 AÊ , c 5 111.0 AÊ ,
and angles a 5 b 5 g 5 908. There are two IMDPH monomers per1985; Hedstrom and Wang, 1990). In contrast, nucleo-
asymmetric unit.side analog inhibitors that are competitive with IMP,
such as mizoribine and ribavirin phosphate, are more
Phasing, Model Building, and Refinementlikely to recognize the consensus nucleotide phosphate-
The structure was determined at 4.0 AÊ resolution by multiple isomor-
binding site found in other enzymes and are thus likely phous replacement, using data from nine heavy-atom derivatives.
to be less specific than MPA. The program PHASES (Furey and Swaminathan, 1996) was used for
all heavy-atom parameter refinement, multiple isomorphous re-
placement phasing, solvent flattening, and phase combination. Ow-
Conclusion ing to overlap of heavy atom sites between derivatives and a sharp
We have determined thehigh resolution crystal structure increase in nonisomorphism, data beyond 4 AÊ was not helpful for
initial multiple isomorphous replacement phasing. The overall meanof IMPDH in complex with an IMP reaction intermediate
figure of merit to 4.00 AÊ resolution was 0.79. Cycles of model building(XMP*) and MPA. IMPDH is a key enzyme in the de novo
(Quanta 4.1, Molecular Simulations), solvent flattening, phase com-pathway of purine biosynthesis in B and T cells, and
bination, and phase extension, along with positional refinementMPA is the active metabolite of a recently approved
(Brunger, 1993), simulated annealing, and torsional dynamics (Rice
immunosuppressive drug. The structure reveals atomic and Brunger, 1994), were used to complete refinement of the struc-
level details of the enzymatic mechanism of IMPDH and ture. Although the presence of the subdomain (residues 110±244)
in the crystals has been confirmed by gel analysis, electron densitythe nature of the inhibition of IMPDH by MPA. The active
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for this region remainspoor, particularly for one of thetwo molecules D.J., Jr., Nelson, P.H., Patterson, J.W., Jr., Rohloff, J.C., Sjogren,
E.B., Smith, D.B., Waltos, A.M., Weikert, R.J., Garcia, A.C., Zertuche,in the asymmetric unit. The current model contains IMPDH residues
11±120, 178±420 (233±420 for the less well-ordered molecule), and M.F., Andrade, F.F., Hernandez, M.T.L., Murra, F.X.T., and Martin,
T.A.T. (1995). 5-Substituted Derivatives of Mycophenolic Acid. World437±514, as well as 202 solvent molecules, two potassium ions, two
IMP thioimidates, and two MPA molecules. The R-factor is 21.7% Patent WO 95/22538.
against all observed data (36069 reflections) between 8.0±2.6 AÊ Blundell, T.L., and Johnson, L.N. (1976). Protein Crystallography
resolution. The free R value is 28.5% for 3617 reflections set aside (New York: Academic Press).
at the start of the refinement. Atomic coordinates for IMPDH will be
Bork, P., Gellerich, J., Groth, H., Hooft, R., and Martin, F. (1995).submitted to the Brookhaven Protein Data Bank for release 1 year
Divergent evolution of a b/a barrel subclass: detection of numerousfrom the date of publication of this manuscript.
phosphate-binding sites by motif search. Protein Sci. 4, 268±274.
Brunger, A.T. (1993). X-PLOR: A System for X-Ray CrystallographyMutagenesis, Measurement of Specific Activity
and NMR (New Haven, Connecticut: Department of Molecular Bio-Mutations were made in the human type II IMPDH cDNA cloned into
physics and Biochemistry, Yale University).a pT7 blue vector (Novagen) by a four-primer polymerase chain
reaction (PCR) method (Rashchian et al., 1992) using Pfu DNA poly- Carr, S.F., Papp, E., Wu, J.C., and Natsumeda, Y. (1993). Character-
merase (Stratagen). PCR products were digested with appropriate ization of human type I and type II IMP dehydrogenases. J. Biol.
restriction enzymes and cloned into unique sites within IMPDH Chem. 268, 27286±27290.
cDNA. Mutants were sequenced in the area containing PCR prod- Carson, M. (1991). Ribbons 2.0. J. Appl. Cryst. 24, 958±961.
ucts and the surrounding restriction sites. The full-length IMPDH
Collart, F.R., and Hubermann, E. (1988). Cloning and sequence anal-cDNA carrying the confirmed mutation was then subcloned into a
ysis of the human and Chinese hamster inosine-59-monophosphatepSPC27 vector in the IMPDH deficient Escherichia coli strain H712
dehydrogenase cDNAs. J. Biol. Chem. 263, 15769±15772.(Nijkamp and Haan, 1967). 500 ml cultures were grown at 378C for
Collart, F.R., and Hubermann, E. (1990). Expression of IMP dehydro-14±16 hr after isopropyl-b-D-thiogalactopyranoside induction and
genase in differentiating HL-60 cells. Blood 75, 570±576.typically yielded 2 g of cell paste. Cells were resuspended in 50 mM
Tris (pH 8.0), 150 mM KCl, 3 mM EDTA, 2 mM dithiothreitol buffer Collart, F.R., Chubb, C.B., Mirkin, B.L., and Huberman, E. (1992).
containing 10% urea, and then lysed by addition of lysozyme (1 Increased inosine-5-monophosphate dehydrogenase gene expres-
mg/g cell paste) and sonication. IMPDH wild-type and mutant pro- sion in solid tumor tissues and tumor cell lines. Cancer Res. 52,
teins were precipitated from crude lysates by 25% w/v ammonium 5826±5828.
sulfate. Up to 150 mg of at least 65%±70% pure IMPDH was obtained Cooney, D., Hamel, E., Cohen, M., Kang, G.J., Dalal, M., and Mar-
by this single purification step. The partially purified IMPDH was quez, V. (1987). A simple method for the rapid determination of
resuspended in 50 mM Tris (pH 8.0), 100 mM KCl, 3 mM EDTA, 2 the stereospecificity of NAD-dependent dehydrogenases applied to
mM dithiothreitol, 10% glycerol buffer and used for kinetic analysis. mammalian IMP dehydrogenase and bacterial NADH peroxidase.
Biochim. Biophys. Acta 916, 89±93.
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